je.st
news
Merck Completes Tender Offer to Acquire Idenix
2014-08-05 12:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) at a purchase price of $24.50 per share. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Steve Cragle, 908-423-3461orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: offer
acquire
tender
completes
Category:Biotechnology and Pharmaceuticals